SAD and MAD Study With IV and SC Doses of ARGX-117 (ARGX-117)
First-In-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous and Subcutaneous Doses of ARGX-117 Co-mixed With rHuPH20
Sponsor: argenx
A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by argenx and has accumulated 9 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
May 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- argenx
For direct contact, visit the study record on ClinicalTrials.gov .